• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Diabetic Neuropathy Market 2014-2018 - Product Image

Global Diabetic Neuropathy Market 2014-2018

  • Published: May 2014
  • Region: Global
  • 55 pages
  • TechNavio
R&D Investment Leading to Better Treatments for Diabetic Neuropathy

FEATURED COMPANIES

  • Actavis plc
  • Cephalon Inc.
  • Eli Lilly and Co.
  • MEDA Pharma GmbH & Co. KG
  • Pfizer Inc.
  • MORE

About Diabetic Neuropathy

Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.

The analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 READ MORE >

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Geographical Segmentation
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Trends and their Impact
15. Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Market Share Analysis 2013
15.3 Other Prominent Vendors
16. Key Vendor Analysis
16.1 Pfizer Inc.
16.1.1 Business Overview
16.1.2 Key Information
16.1.3 SWOT Analysis
16.2 Eli Lilly and Company
16.2.1 Business Overview
16.2.2 Business Segmentation
16.2.3 Key Information
16.2.4 SWOT Analysis
16.3 Janssen Pharmaceuticals Inc.
16.3.1 Business Overview
16.3.2 Key Information
16.3.3 SWOT Analysis
17. Pipeline Analysis
17.1 Phase III Analysis
17.2 Phase II Analysis
17.3 Phase I Analysis
17.4 Discontinued Projects
17.5 Projects on Hold
17.6 Promising Pipeline Molecules
17.6.1 Phase III Promising Pipeline Molecules
17.6.2 Phase II Promising Pipeline Molecules
17.7 Other First-in-class Pipeline Molecules:
18. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Diabetic Neuropathy Market 2013-2018 (US$ billion)
Exhibit 3: Global Diabetic Neuropathy Market by Geographical Segmentation 2013
Exhibit 4: Eli Lilly and Company: Business Segmentation
Exhibit 5: Diabetic Neuropathy Pipeline Snapshot 2013
Exhibit 6: Discontinued Pipeline Molecules on the basis of MOA

Commenting on the report, an analyst from the team said: “R&D activities in the Diabetic Neuropathy sector are growing in terms of an increase in the number of mergers and acquisitions. Big pharmaceutical companies take up later-stage products from small companies, where efficacy has already been demonstrated, thereby cutting down initial R&D expenditure. For instance, in March 2013, BioDelivery Sciences International Inc. in-licensed a patented topical formulation of clonidine gel from Arcion Therapeutics Inc. for the treatment of indications including diabetic neuropathy. In July 2013, Acorda Therapeutics acquired two candidates for neuropathic pain including NP-1998, a topical capsaicin solution, from NeurogesX Inc. In-licensing by big pharmaceutical companies, in turn, diverts funds to be spent by the smaller companies on marketing and commercialization to R&D development.”

According to the report, the Global Diabetic Neuropathy market is driven by several factors, of which the increase in the global diabetic population is one of the major drivers. The incidence and prevalence rate of diabetes is growing continuously, mainly because of the adoption of a sedentary form of life and unhealthy eating habits accompanied by increased life expectancy. In 2013, globally, around 382 million adults were suffering from diabetes, and the number is expected to increase to 592 million by 2035. Thus, an increase in the diabetic population might lead to an increase in the number of people suffering from diabetes-associated complications.
Further, the report states that one of the main challenges is the high failure rate of pipeline drugs in clinical trials. Lack of simple, sensitive tests for diagnosis, and assessment of diabetic neuropathy hinders the effective evaluation of pipeline drugs during clinical trials.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

- Eli Lilly and Co.
- Janssen Pharmaceuticals Inc.
- Pfizer Inc.
- Actavis plc
- Cephalon Inc.
- MEDA Pharma GmbH & Co. KG

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos